COMP <GO>
NBIX vs ABBV // FORWARD P/E MULTIPLE
Neurocrine Biosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NBIX 9
— ABBV 6
▲ FORWARD P/E MULTIPLE LEADER: NBIX
LAST: $146.10 (-0.19%) • MKT CAP: $14.88B
forward-pe
26.1x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 29.00% | -13.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 33.3x | -10.50 | NBIX | /valuation <GO> |
| Free Cash Flow Yield | 5.03% | 3.47% | +1.56 | NBIX | /fcf-yield <GO> |
| Operating Margin | 21.60% | 24.60% | -3.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 16.70% | 6.90% | +9.80 | NBIX | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 8.60% | +12.80 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 5.33 | +2.80 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | NBIX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.5 | 72.8 | -17.32 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 1.15 | -0.02 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.1x | 113.1x | -87.00 | NBIX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.88B | $513.86B | -$498.98B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | ABBV REV | NBIX GROSS % | ABBV GROSS % | NBIX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $61.16B | 98.2% | 70.2% | $748.7M | $17.82B |
| FY 2024 | $2.36B | $56.33B | 98.6% | 70.0% | $557.2M | $17.83B |
| FY 2023 | $1.89B | $54.32B | 44.0% | 44.0% | $305.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
ABBV // BETA 1.15